Walleye Trading
CARM

Walleye Trading’s Carisma Therapeutics CARM Stock Holding History

Walleye Trading’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-10
Closed – – 5299
2015
Q3 		$0 Sell
10
-45
-82% -$2.77K ﹤0.01% 4987
2015
Q2 		$3K Buy
+55
New +$7.76K ﹤0.01% 4603

Other funds holding CARM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
FVFIGP
Flagship Ventures Fund IV General Partner Cambridge, Massachusetts $585M AUM
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RCM
Rotella Capital Management Bellevue, Washington $1.47M AUM 12.32% 1-Year Est. Return

Walleye Trading's CARM Position: Q4 2015 in Review

Walleye Trading sold out of Carisma Therapeutics (CARM) in Q4 2015, closing a stake of 10 shares.

Walleye Trading first reported a position in CARM in Q2 2015 and held it in 2 quarters. The position peaked at $3K in Q2 2015. 29 funds tracked by Wall St. Rank hold CARM as of Q4 2015.

  • Walleye Trading reported no remaining Carisma Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Walleye Trading sold 10 Carisma Therapeutics shares in Q4 2015.
  • Walleye Trading first reported a position in Carisma Therapeutics in Q2 2015 and held it in 2 quarters.
  • Walleye Trading's Carisma Therapeutics position peaked at $3K in Q2 2015.
  • 29 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2015.

Based on Walleye Trading's 13F filing for Q4 2015, filed 16 Feb 2016.